Molecular Analysis Refines Diagnosis, Enables Personalized Treatment for Pediatric CNS Tumors
Of the patients who completed follow-up, 60% had a targeted therapy recommendation.
Of the patients who completed follow-up, 60% had a targeted therapy recommendation.
The median duration of response was not reached at a median follow-up of 26 months.
There was no significant difference in rates of secondary neoplasms at 10 years.
A global survey of health care providers revealed significant knowledge gaps about childhood central nervous system tumors.
Systemic inflammatory biomarkers may be useful in the differential diagnosis of primary central nervous system lymphoma and high-grade glioma.
No significant association was seen between maternal hormonal contraception use and CNS tumors in children younger than 20 years.
Incidence rates decreased overall but increased among children and adolescents.
A 1:1 ratio of THC to CBD proved superior to a 4:1 ratio.
Therapy intensification with carboplatin improved five-year event-free survival in children with high-risk group 3 medulloblastoma only.
While there is short-term excess mortality, cumulative survival is similar to the general population.